trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Letrozole is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Letrozole is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer?

Yes. Letrozole is a well-established aromatase inhibitor indicated for the adjuvant endocrine treatment of hormone receptor-positive early breast cancer in postmenopausal women.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The claim is specific, empirical, and falsifiable. Retrieved papers such as [0], [3], and [11] explicitly support the use of letrozole as an adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer. There are no contradicting papers in the provided set.

Evidence for · 3
Use of aromatase inhibitors in the adjuvant treatment of breast cancer.
1999
Identifies letrozole as an important new-generation aromatase inhibitor being investigated for the treatment of postmenopausal women with early breast cancer.
Get citation
Baum, M. (1999). Use of aromatase inhibitors in the adjuvant treatment of breast cancer.. doi.org. https://doi.org/10.1677/erc.0.0060231

See more details
More for · 2
Aromatase Inhibitors
2026
Confirms that aromatase inhibitors, including letrozole, are endocrine therapies used primarily to treat hormone receptor-positive breast cancer in postmenopausal women in adjuvant settings.
Get citation
MK, F. & P, P. (2026). Aromatase Inhibitors. europepmc.org. https://europepmc.org/article/MED/32491779

Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.
2026
Utilizes letrozole as a core component of adjuvant and neoadjuvant endocrine therapy regimens in hormone receptor-positive early breast cancer trials.
Get citation
P, C., T, P., J, L., H, H., E, R., RM, C., CX, M., AC, W., T, C., P, T., JM, F., A, M., F, S., G, V., J, G., T, d. L. M. R., & A, P. (2026). Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.. doi.org. https://doi.org/10.1177/17588359261467380

What does the evidence say?

The claim is specific, empirical, and falsifiable. Retrieved papers such as [0], [3], and [11] explicitly support the use of letrozole as an adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer. There are no contradicting papers in the provided set.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work